Phase II Randomized Study of Hypoxia-Adjusted Radiotherapy Dose Escalation Using 18F FMISO PET CT in Head and Neck Squamous Cell Carcinoma
Led by Rajiv Gandhi Cancer Institute & Research Center, India · Updated on 2025-01-17
124
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying head and neck squamous cell carcinoma to understand how increasing radiation doses to low-oxygen hypoxic areas within tumors affects cancer control, treatment feasibility, and side effects. This phase II trial compares different radiation approaches combined with standard chemotherapy using cisplatin. The goal is to improve locoregional control of the cancer while monitoring safety.
Participants undergo imaging with 18F FMISO PET scans to identify tumor oxygen levels. Those without hypoxia receive standard chemoradiation, while patients with hypoxia are randomized to either standard chemoradiation or an escalated radiation dose targeted to hypoxic tumor areas using advanced planning techniques. Radiation is delivered in daily fractions over several weeks with concurrent weekly cisplatin chemotherapy. The higher dose group receives an additional boost of 10 Gy to the hypoxic sub-volumes.
Throughout the study, participants will have repeated imaging and assessments to adjust treatment volumes and monitor response. Researchers will evaluate locoregional control over 24 months, along with survival and relapse-free survival. Safety and treatment tolerability will also be followed. The total participation spans the treatment period and follow-up assessments up to two years to measure outcomes and side effects.
CONDITIONS
Brief Title
Dose Escalation Using Hypoxia-adjusted Radiotherapy
Research Team
S
Sarthak Tandon, DNB
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Rajiv Gandhi Cancer Institute & Research Center, India
Lead Sponsor
Varian, a Siemens Healthineers Company
Collaborating Sponsor
Who Can Participate
Age: 18Years - 70Years
All Genders
Eligibility Criteria
You may qualify if you...
Age between 18 and 70 years
Willingness to sign informed consent (written or video)
Performance status ECOG 0 to 2
Histologically confirmed squamous cell carcinoma
Tumor sites include oral cavity, oropharynx, hypopharynx, and larynx
Adequate bone marrow function within last 14 days (Hb > 10g/dl, TLC > 4,000/cumm, Platelet > 150,000/cumm)
Normal liver and kidney function
Nutritional and dental assessment completed before study inclusion
You will not qualify if you...
HPV (p16) positive tumors
Prior surgery or radiation therapy for head and neck cancer
T1/T2 glottis tumors
Metastatic disease or disease not suitable for definitive locoregional treatment
Medical conditions preventing radiation or cisplatin chemotherapy
Pregnancy or lactation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 6 to 7 weeks
Participants receive radiotherapy with or without dose escalation to hypoxic tumor areas, combined with concurrent weekly cisplatin chemotherapy if clinically indicated. Treatment lasts 6 to 7 weeks with radiation doses delivered in daily fractions.
Daily visits for radiation therapy and weekly visits for chemotherapy
Follow-up
Duration - Up to 24 months
Participants are monitored for locoregional control, overall survival, and relapse-free survival after treatment completion for up to 24 months.
Scheduled follow-up visits over 24 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Phase 1 Study of 89Zr Panitumumab PETCT to Detect Metastases in Head and Neck Squamous Cell Carcinoma
Phase II Study Comparing Stereotactic Body Radiation Therapy and Traditional Radiation for Palliative Treatment of Head and Neck Squamous Cell Carcinoma
Phase 1 Study of Intratumoral ONM-501 Alone and with Cemiplimab for Advanced Solid Tumors and Lymphomas
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Tempus AI Observational Study on Multi-Omic Biomarker Profiling in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Phase III Study Comparing Standard and Hyperfractionated Radiotherapy in Head and Neck Squamous Cell Carcinoma Patients with High-Risk Tumors
Phase 0 Multicenter Study to Explore the Effects of Small Doses of PBA-0111 Injected Directly Into Tumors in Adults With Certain Solid Tumors
Phase 1 Study Evaluating Safety and Tolerability of CTX-8371 in Adults With Advanced Cancers Receiving Intravenous Infusions
First-in-Human Study Evaluating EPI-326 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
Evaluating TER-2013 Alone and with Fulvestrant for Solid Tumors with AKTPI3KPTEN Pathway Alterations in a Phase 12 Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
Lise Saksø Mortensen, Jørgen Johansen, Jesper Kallehauge...
Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.
Steffi U Pigorsch, Jan J Wilkens, Severin Kampfer...
Failure patterns of head and neck squamous cell carcinoma treated with radical radiotherapy by intensity modulated radiotherapy technique using focal volume and dosimetric method.